Notice détaillée
Titre
UPHAN
Formal Name (French)
Unité du Prof. Hantschel
Formal Name (English)
Prof. Hantschel Group
Lab Manager
Hantschel, Oliver
Group ID
U12375
Auteurs affilié
Desbaillets, Nicolas Pierre
Gencer Akçok, Emel Basak
Gerig, Barbara
Hantschel, Oliver
Hornakova, Tekla
Kuzyk, Orest
Kükenshöner, Tim
La Sala, Grégory
Lamontanara, Allan Joaquim
Mann, Gregory
Pereira Duarte, Daniel
Pereira Pinho, Sara Raquel
Reckel, Sina Maren
Schmit, Nadine Eliane
Gencer Akçok, Emel Basak
Gerig, Barbara
Hantschel, Oliver
Hornakova, Tekla
Kuzyk, Orest
Kükenshöner, Tim
La Sala, Grégory
Lamontanara, Allan Joaquim
Mann, Gregory
Pereira Duarte, Daniel
Pereira Pinho, Sara Raquel
Reckel, Sina Maren
Schmit, Nadine Eliane
Institut
ISREC
Faculté
SV
Note
Members of UPHAN (infoscience-uphan)
Lien extérieur
http://hantschel-lab.epfl.ch
Publications
An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
Voir toutes les publications (82)
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
Voir toutes les publications (82)
Le document apparaît dans
Authorities > Lab